CRPC cells and tumours will eventually become therapy-resistant even to a full-blockade of AR through ADT and second-generation AR antagonists co-treatment via adaptive signalling [27], which may include a variety of different pathways that activate AR signalling or may select for those AR mutants that not only overcome antagonism but are instead rather strongly activated by a specific AR antagonist. The gene discussed is AR; the disease is neoplasm.